110 related articles for article (PubMed ID: 9426433)
1. Improved selection of patients for reoperation for medullary thyroid cancer by imaging with radiolabeled anticarcinoembryonic antigen antibodies.
Juweid M; Sharkey RM; Swayne LC; Goldenberg DM
Surgery; 1997 Dec; 122(6):1156-65. PubMed ID: 9426433
[TBL] [Abstract][Full Text] [Related]
2. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
[TBL] [Abstract][Full Text] [Related]
3. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen.
Juweid M; Sharkey RM; Behr T; Swayne LC; Rubin AD; Herskovic T; Hanley D; Markowitz A; Dunn R; Siegel J; Kamal T; Goldenberg DM
J Clin Oncol; 1996 Apr; 14(4):1209-17. PubMed ID: 8648376
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
Barbet J; Peltier P; Bardet S; Vuillez JP; Bachelot I; Denet S; Olivier P; Leccia F; Corcuff B; Huglo D; Proye C; Rouvier E; Meyer P; Chatal JF
J Nucl Med; 1998 Jul; 39(7):1172-8. PubMed ID: 9669389
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer.
Kebebew E; Kikuchi S; Duh QY; Clark OH
Arch Surg; 2000 Aug; 135(8):895-901. PubMed ID: 10922248
[TBL] [Abstract][Full Text] [Related]
6. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen.
Juweid M; Sharkey RM; Behr T; Swayne LC; Rubin AD; Hanley D; Herskovic T; Markowitz A; Siegel J; Goldenberg DM
Cancer Res; 1995 Dec; 55(23 Suppl):5946s-5951s. PubMed ID: 7493375
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies.
Juweid M; Sharkey RM; Behr T; Swayne LC; Herskovic T; Pereira M; Rubin AD; Hanley D; Dunn R; Siegel J; Goldenberg DM
J Nucl Med; 1996 Jun; 37(6):905-11. PubMed ID: 8683309
[TBL] [Abstract][Full Text] [Related]
8. Immunoscintigraphy using 111In-labeled F(ab')2 fragments of anticarcinoembryonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma.
Vuillez JP; Peltier P; Caravel JP; Chetanneau A; Saccavini JC; Chatal JF
J Clin Endocrinol Metab; 1992 Jan; 74(1):157-63. PubMed ID: 1727816
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
Oudoux A; Salaun PY; Bournaud C; Campion L; Ansquer C; Rousseau C; Bardet S; Borson-Chazot F; Vuillez JP; Murat A; Mirallié E; Barbet J; Goldenberg DM; Chatal JF; Kraeber-Bodéré F
J Clin Endocrinol Metab; 2007 Dec; 92(12):4590-7. PubMed ID: 17878252
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
Juweid ME; Hajjar G; Swayne LC; Sharkey RM; Suleiman S; Herskovic T; Pereira M; Rubin AD; Goldenberg DM
Cancer; 1999 Apr; 85(8):1828-42. PubMed ID: 10223579
[TBL] [Abstract][Full Text] [Related]
11. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
12. Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma.
Magnani P; Paganelli G; Songini C; Samuel A; Sudati F; Siccardi AG; Fazio F
Br J Cancer; 1996 Sep; 74(5):825-31. PubMed ID: 8795589
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
[TBL] [Abstract][Full Text] [Related]
14. Improved results of cervical reoperation for medullary thyroid carcinoma.
Moley JF; Dilley WG; DeBenedetti MK
Ann Surg; 1997 Jun; 225(6):734-40; discussion 740-3. PubMed ID: 9230814
[TBL] [Abstract][Full Text] [Related]
15. Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
Bodet-Milin C; Faivre-Chauvet A; Carlier T; Rauscher A; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
J Nucl Med; 2016 Oct; 57(10):1505-1511. PubMed ID: 27230928
[TBL] [Abstract][Full Text] [Related]
16. [Detection of residual lesions and metastases of medullary thyroid cancer].
Murat A
Ann Endocrinol (Paris); 1996; 57(1):27-32. PubMed ID: 8734286
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin and somatostatin analogues in medullary thyroid carcinoma.
O'Byrne KJ; O'Hare N; Sweeney E; Freyne PJ; Cullen MJ
Nucl Med Commun; 1996 Sep; 17(9):810-6. PubMed ID: 8895910
[TBL] [Abstract][Full Text] [Related]
18. Preoperative localization of occult medullary carcinoma of the thyroid gland with single-photon emission tomography dimercaptosuccinic acid.
Udelsman R; Ball D; Baylin SB; Wong CY; Osterman FA; Sostre S
Surgery; 1993 Dec; 114(6):1083-9. PubMed ID: 8256211
[TBL] [Abstract][Full Text] [Related]
19. Functional nuclear medicine imaging of medullary thyroid cancer.
Bozkurt MF; Uğur O; Banti E; Grassetto G; Rubello D
Nucl Med Commun; 2008 Nov; 29(11):934-42. PubMed ID: 18836370
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Fiche M; Gautherot E; Barbet J; Chatal JF
J Nucl Med; 1998 Sep; 39(9):1608-13. PubMed ID: 9744353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]